Vanlev en es it fr

Vanlev Brand names, Vanlev Analogs

Vanlev Brand Names Mixture

  • No information avaliable

Vanlev Chemical_Formula

C19H24N2O4S2

Vanlev RX_link

No information avaliable

Vanlev fda sheet

Vanlev msds (material safety sheet)

Vanlev Synthesis Reference

No information avaliable

Vanlev Molecular Weight

408.537 g/mol

Vanlev Melting Point

No information avaliable

Vanlev H2O Solubility

No information avaliable

Vanlev State

Solid

Vanlev LogP

2.541

Vanlev Dosage Forms

No information avaliable

Vanlev Indication

For the treatment of hypertension

Vanlev Pharmacology

Omapatrilat is used to treat hypertension. Vasopeptidase inhibitor that simultaneously inhibits angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). Omapatrilat lowers blood pressure by inhibiting the action of the angiotensin converting enzyme (ACE), which causes blood vessels to constrict. But unlike other drugs, omapatrilat also inhibits another enzyme known as neutral endopeptidase (NEP), which helps blood vessels relax. Omapatrilat demonstrated greater reduction in blood pressure than the ACE inhibitor lisinopril in individuals with salt-sensitive hypertension who typically do not respond well to ACE inhibitors.

Vanlev Absorption

The absolute oral bioavailability of omapatrilat is 20% to 30% and the absorption is not affected by food intake.

Vanlev side effects and Toxicity

Side effects include hyperkalemia, cough, hypotension, increased SrCr, and dizziness. Dizziness, diarrhea, vision disturbance, hypotension and angioedema

Vanlev Patient Information

No information avaliable

Vanlev Organisms Affected

Humans and other mammals